This blog tracks updates to the Blood Sugar 101 Web site.


Wednesday, October 18, 2017

New Fast Acting Insulin Fiasp and new GLP-1 Agonist Semaglutide Mentioned in Relevant Web Pages

Pages changed: GLP-Agonists and Insulin for Type 2 Diabetes

Brief mention made of the upcoming approval of semaglutide, the first GLP-1 agonist in pill form and of Fiasp, a new fast-acting insulin which is similar to Apidra in that it can be injected just after eating and still be effective.

Thursday, May 25, 2017

Link Added to Gary Scheiner's Review on the Afrezza Page of Blood Sugar 101

Page Changed: Inhaled Insulin: Afrezza

Text Added:

A review of Afrezza written by Gary Scheiner, a Certified Diabetes Educator whose book I have often recommended, came out in May of 2017 and may be helpful to people considering trying this insulin. I trust Scheiner a lot more than I do random people tweeting, who may or may not be on the payroll of the company making this stuff. You can read his review in his newsletter, HERE. Unfortunately, there is still no one with this kind of preexisting credibility in the online diabetes community reporting on their use of Afrezza for Type 2 Diabetes. This may simply be because doctors are so resistant to prescribing fast acting insulin to people with Type 2 diabetes.

Tuesday, May 16, 2017

FDA Puts Warning of Doubled Risk of Amputation on Invokana Label

Page changed:  SGLT2 Inhibitors, Farxiga, Invokana, Jardiance.Dangerous New Drugs
Note: "Questionable" has been changed to "Dangerous in this page title.

Text Added:

Doubled Risk of Lower Limb Amputations

On May 16, 2017 the FDA ordered that a black box warning be added to the prescribing information for Invokana saying that it doubled the risk of experiencing an amputation. You can read the report about this very important warning in this Medscape news bulletin.


Monday, February 13, 2017

EMA Orders SGLT-2 Drug Labels to Warn of Increased Risk of Lower Limb Amputations

Page Changed: SGLT2 Inhibitors, Farxiga, Invokana, Jardiance. Questionable New Drugs

Added Text: 

Increased Risk of Lower Limb Amputations

As reported on Medscape The European Medicines Agency (EMA) which is the European equivalent of the FDA announced on February 10, 2017 that a warning stating that the sodium glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes may increase the risk for lower-limb amputation should be included in the prescribing information for all drugs in this class.

In Medscape's words, "The warning from EMA's Pharmacovigilance Risk Assessment Committee (PRAC) issued today cites data from two ongoing clinical trials with canagliflozin (Invokana, Vokanamet, Janssen) in patients at high risk for cardiovascular events, Canagliflozin Cardiovascular Assessment Study (CANVAS) and a related study of renal end points, CANVAS-R."

Quoting the EMA the article points out that "In a 4.5-year interim analysis of CANVAS, the independent monitoring committee for the trial found that the rate of amputations per every 1000 patients was equivalent to seven for 100 mg/day and five for 300 mg/day of canagliflozin compared with three per 1000 patients taking placebo. Most of the amputations were of toes." Note that this means that there were from one and two thirds more to more than twice as many amputations in the group taking the drug as occurred in the placebo group.

As you can see if you read the comments to the Medscape new release, some people claiming to be doctors and a pharmacist immediately argued that this was because the patients given the SGLT-2 inhibitors were sicker and more likely to have amputations. People posting comments on Medscape are not required to reveal if they are on the payroll of the companies who are earning several billion dollars a year selling these heavily advertised new drugs. Nor are they required to validate their identity, so any employee of a drug company could post these comments using a made up doctor's name.

Lest you be swayed by their arguments against believing the EMA's experts, note that this data was from a controlled study. This means that both the group taking the drug and the group taking a placebo were matched for characteristics which would have included their blood sugars, age, and time since diagnosis. Since the groups had the same characteristics, the higher rate of amputations is very likely to be a result of something the drug does to the blood supply of the toes. The EMA doesn't lightly decide to add a serious warning to the label of a drug.

New Brazilian Portuguese version of the "How To Lower Your Blood Sugar" Flyer uploaded

Page Changed: How to Lower Your Blood Sugar

Added a link to a Brazilian Portuguese translation of the flyer.
The PDF can be downloaded here: http://www.phlaunt.com/diabetes/BrazilianPortugueseFlyer.pdf .

Friday, January 20, 2017

A link to The Blood Sugar 101 Monthly Challenge Has Been Added to Our Main Web Site

Page Added:Hold Yourself Accountable - Join the Blood Sugar 101 Monthly Challenge

This page links to the monthly diet/blood sugar challenge that was created in response to requests from members of our Blood Sugar 101 FaceBook Page .

A new challenge will start each month. The page describes how the challenge works and how we hope to collect useful real-world experience data from it.

Thursday, October 27, 2016

New Page Added: Common Phosphate Additives Damage Your Kidneys and Cardiovascular System

Page Added:Common Phosphate Additives Damage Your Kidneys and Cardiovascular System This new page on the main Blood Sugar 101 Web Site combines information that was posted in several blog posts in 2013. It is now also linked to from the Diabetic Kidney Disease page.